3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
6
Thoracic
2
Gynecologic
2
Gastrointestinal
2
Dermatologic
2
Breast
2
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
CNS
1
Conditions
Lymphoma, Non-Hodgkin
21
Leukemia, Lymphocytic, Chronic, B-Cell
14
Lymphoma
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
9
Lymphoma, Follicular
9
Leukemia, Myeloid, Acute
9
Hodgkin Disease
7
Lymphoma, Mantle-Cell
6
Lymphoma, Large B-Cell, Diffuse
6
Leukemia
6
Myelodysplastic Syndromes
5
Multiple Myeloma
5
Lymphoma, B-Cell, Marginal Zone
5
Lymphoma, B-Cell
5
Hematologic Neoplasms
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Burkitt Lymphoma
4
Stomach Neoplasms
3
Recurrence
3
Lymphoma, Large-Cell, Immunoblastic
3
Colorectal Neoplasms
3
Waldenstrom Macroglobulinemia
2
Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Leukemia, Myelomonocytic, Juvenile
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Uterine Cervical Neoplasms
1
Thrombocythemia, Essential
1
Interventions
Vorinostat
3
Azacitidine
3
venetoclax
2
trametinib
2
ruxolitinib
2
pertuzumab
2
palbociclib
2
olaparib
2
durvalumab
2
dabrafenib
2
copanlisib
2
aflibercept
2
abiraterone
2
Sunitinib
2
Specimen Handling
2
Sirolimus
2
Nivolumab
2
Immunoglobulin G
2
HhAntag691
2
Doxorubicin
2
Disulfides
2
Dasatinib
2
Cyclophosphamide
2
Biopsy
2
Afatinib
2
Ado-Trastuzumab Emtansine
2
2C4 antibody
2
ulixertinib
1
tremelimumab
1
trastuzumab biosimilar HLX02
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Prostatic Neoplasms
×
Interleukin-2
×
Lymphoid
×
Clear all
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled